- Home
- SRPT
as 03-25-2025 10:41am EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 9.8B | IPO Year: | 1997 |
| Target Price: | $164.05 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $72.17 - $173.25 | Next Earning Date: | 04-30-2025 |
| Revenue: | $1,901,979,000 | Revenue Growth: | 52.97% |
| Revenue Growth (this year): | 67.83% | Revenue Growth (next year): | 25.66% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nicaise Claude | SRPT | Director | Mar 12 '25 | Sell | $99.64 | 2,491 | $248,203.24 | 27,812 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
StockStory
2 days ago
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Motley Fool
2 days ago
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
StockStory
5 days ago
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
Zacks
5 days ago
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Zacks
5 days ago
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
Zacks
6 days ago
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Insider Monkey
6 days ago
Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.